VERSATILE-003: A phase 3, randomized, open-label trial of PDS0101 and pembrolizumab compared with pembrolizumab for first-line treatment of patients with HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma.

Authors: Katharine Andress Rowe Price, Kevin Joseph Harrington, Francis P. Worden, Ricard Mesia, Caroline Even, David Schaaf, Sally Jones, Nabil F. Saba, Robert I. Haddad

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps6111

Source: Full article

---

Abstract

TPS6111